Skip to main content

Security report for axonis.us

Axonis Therapeutics, Inc. · Healthcare · United States

Medium risk. 9 critical or high findings in Security headers, GDPR outside view and 1 other check.

Security score

60/100

Risk levelMedium

0–100, higher is better. How it is calculated

Axonis Therapeutics, Inc. is a Boston-based biotechnology company specializing in neuro-focused drug development targeting KCC2, a key protein involved in neuronal inhibition. The company leverages proprietary technology spun out from leading academic institutions and has secured significant Series A funding to advance its first-in-class oral KCC2 potentiator drug, AXN-027, aimed at treating epilepsy, pain, and other CNS disorders. The website reflects a professional and focused business presence with clear scientific and investment messaging. Technically, the website is built on WordPress using Elementor and Astra theme, with modern web technologies and SEO optimizations in place. The site is mobile-optimized and performs moderately well, though some accessibility features could be improved. Security posture is adequate with HTTPS enforced and domain protections, but lacks advanced security headers and DNSSEC. No direct contact emails or phone numbers are published; contact is via a form. Privacy and cookie policies are minimal, with only an FCOI policy found. No incident response or vulnerability disclosure information is provided, indicating room for improvement in transparency and compliance. Overall, the website presents a credible and professional biotech company with solid business and technical foundations but could enhance security and privacy compliance to strengthen trust and regulatory adherence.

Scanned

NIS2 and GDPR posture

GDPR outside view
35/ 100 · High
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

9 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Privacy Policy found

      GDPR requires a clear and accessible privacy policy

      What to do: Add a comprehensive privacy policy page and link to it prominently

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

Need hands-on remediation? Email guard@offseq.com

Keep watching axonis.us

This scan found 25 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
52
Security headers
15
Email security
85
DNS health
75
Network security
100
GDPR outside view
35
Average
60

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Axonis Therapeutics positions itself as an emerging leader in the neuropharmaceutical space, focusing on KCC2-targeted therapies. The company benefits from strong academic roots and substantial venture funding, indicating growth potential. Its business model centers on drug discovery and clinical development for neurological disorders, targeting markets such as epilepsy and pain management. The website content and structure support investor relations and scientific credibility, though direct customer engagement channels are limited. The LinkedIn presence supports professional networking. No partnerships or subsidiaries are explicitly mentioned, suggesting a focused standalone operation. The company’s recent $115 million Series A financing and planned clinical trials in 2024 highlight active development and market entry efforts. The absence of detailed privacy and security policies may reflect early-stage digital maturity in compliance areas.

Security posture

The website enforces HTTPS with a valid SSL certificate, ensuring encrypted communications. Domain registration includes multiple EPP status protections, reducing risk of unauthorized transfers or deletions. However, the absence of DNSSEC leaves the domain vulnerable to DNS spoofing attacks. No HTTP security headers such as Content-Security-Policy, X-Frame-Options, or Strict-Transport-Security were detected, which are recommended to mitigate common web attacks. No explicit security or incident response policies are published, and no security.txt or vulnerability disclosure mechanisms are present, limiting transparency and readiness for security incidents. The contact methods do not include dedicated security or abuse channels. The site uses common third-party libraries (jQuery, FontAwesome) without detected vulnerabilities but should maintain updates. Overall, the security posture is moderate but could be significantly improved by implementing recommended headers, DNSSEC, and publishing security policies to enhance trust and compliance.

Recommendations

  1. Implement and publish a comprehensive privacy policy and cookie consent mechanism to improve GDPR compliance.
  2. Add HTTP security headers including Content-Security-Policy, X-Frame-Options, and Strict-Transport-Security to enhance web security.
  3. Enable DNSSEC for the domain to protect against DNS spoofing and improve domain security.
  4. Publish a security policy and incident response plan, including a security.txt file and dedicated contact channels for vulnerability reporting.
  5. Enhance accessibility features and conduct regular security audits to maintain a strong security posture.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Axonis Therapeutics, Inc.
Description
Axonis Therapeutics is a Boston-based biotechnology company developing first- and best-in-class neuromedicines targeting KCC2, the critical mediator of inhibition within the brain. They translate breakthrough discoveries from Boston Children’s Hospital, Harvard, and Laval University. They recently closed a $115 million Series A financing and plan first-in-human trials in 2024 for AXN-027, an oral KCC2 potentiator drug for epilepsy, pain, and other CNS pathologies.
Key services
Drug discovery and development, KCC2 potentiator therapies, Neurological disorder treatments
Content quality
good
Branding
consistent

Technology

Stack
WordPress, Elementor, Yoast SEO, jQuery, FontAwesome, Google Fonts
Frameworks
Astra Theme
Platforms
WordPress CMS
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
75/100
Good practices seen
  • HTTPS enforced
  • Domain status includes clientDeleteProhibited and other EPP protections

Analytics and tracking

Services
Google Analytics
Tracking level
minimal
Privacy practices
basic

Advertising

Marketing tools
Yoast SEO
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is professionally designed and content-rich for a biotech company.
  2. No privacy or cookie policy explicitly found except an FCOI policy.
  3. No explicit security or incident response policies published.
  4. Contact available only via contact form; no direct emails or phone numbers found.
  5. No vulnerability disclosure or security.txt file present.
  6. SSL is properly configured; no DNSSEC enabled.
  7. Social media presence limited to LinkedIn.
  8. No advertising or affiliate programs detected.
Technical notes

Notes

The website is built on a modern WordPress CMS platform using the Astra theme and Elementor page builder, which provides flexibility and ease of content management. The use of Yoast SEO plugin indicates attention to search engine optimization. External resources include Google Fonts and FontAwesome for styling and icons. JavaScript libraries such as jQuery are used for interactivity. Performance is moderate with video background usage and multiple CSS/JS assets, which could be optimized further. Mobile optimization is good with responsive design elements. Accessibility is basic and could be improved with better ARIA roles and keyboard navigation support. Hosting appears to be managed via GoDaddy, with domain registration consistent and stable. No advanced CDN or caching mechanisms were explicitly detected. Overall, the technical infrastructure supports a professional web presence but has room for performance and security enhancements.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with axonis.us. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review axonis.us.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.